---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000031"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:45:01.079841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q1 net loss $45.3M, cash $355.5M, PDUFA date May 19 for B-VEC

## Summary
- Net loss of $45.3M ($1.76 per share) vs $50.0M loss ($1.99) in Q1 2022.
- Cash, equivalents & investments $355.5M at March 31, 2023.
- R&D expense $12.3M (up from $9.3M); G&A expense $24.0M (up from $15.9M).
- PDUFA date for B-VEC Biologics License Application is May 19, 2023; labeling discussions started in April.
- Topical B-VEC in eye under compassionate use showed vision improvement from hand motion to 20/40 at 7 months.

## SEC filing metadata
- accession: 0001711279-23-000031
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/0001711279-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/krys-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000031
- JSON: https://secwatch.observer/filing/0001711279-23-000031.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000031.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported the quarter ended March 31, 2023 results: net income Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),, EPS $(1.76) and $(1.99), respectively, per common share (basic and diluted).
  - Period: the quarter ended March 31, 2023
  - Net income: Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),
  - EPS: $(1.76) and $(1.99), respectively, per common share (basic and diluted)
  - Result: reported results
  source text: Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99), respectively, per common share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/0001711279-23-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.